MOTS-c vs SS-31
Well Studied vs Well Studied
synergistic Both are mitochondrial peptides with complementary mechanisms.
Molecular Data
MOTS-c SS-31
Weight 2,174.6 Da —
Half-life ~30 minutes ~2 hours
Chain 16 amino acids —
Type Mitochondrial-derived peptide (MDP) Aromatic-cationic tetrapeptide
Key Benefits
MOTS-c
01 Enhanced insulin sensitivity (~30% improvement)
02 Improved glucose metabolism and tolerance
03 AMPK pathway activation
04 Mitochondrial function optimization
05 Exercise performance enhancement (12-15% improvement)
06 Potential lifespan extension (6.4% median increase in mice)
SS-31
01 Directly protects mitochondria
02 Improves cellular energy production (ATP)
03 Reduces oxidative damage
04 Enhances exercise capacity
05 Excellent safety profile in clinical trials
06 Cardioprotective effects
Dosing Protocols
MOTS-c
Start 5mg daily, increase to 10-15mg based on goals / Daily for metabolic support, or 3x weekly for anti-aging
Metabolic health 5-10mg Once daily
Anti-aging protocol 15mg 3x weekly
Exercise performance 10-15mg Pre-workout
Conservative start 5mg Once daily
SS-31
5-10mg general support, 10-40mg clinical/performance protocols / Once daily (morning or pre-workout for athletic use)
General mitochondrial support 5-10mg Once daily
Athletic performance 10-20mg Once daily pre-workout
Clinical protocols 40mg Once daily
Acute cardioprotection 0.25mg/kg/hr Continuous infusion
Side Effects
MOTS-c
Generally well-tolerated in animal studies with minimal side effects
Mild injection site reactions (redness, swelling)
SS-31
Excellent safety profile in clinical trials
No significant side effects reported at therapeutic doses
Mild injection site reactions possible
Safe for long-term use based on current data
Contraindications
Pregnancy or breastfeeding
WADA prohibited substance (banned for athletic competition)
Limited long-term human safety data
Known hypersensitivity to peptides
Pregnancy or breastfeeding (limited data)
Research Evidence
MOTS-c SS-31
Status Well Studied Well Studied
References 5 studies 4 studies
Latest 2025 February 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.